Barcelona - KRAS19 Sep 2022 08:48
I believe this page details the team at Barcelona with a little more information about the compound under evaluation.
http://www.fbg.ub.edu/actualitat/potencial-terapia-molecular-dirigida-contra-cancer-pancrees/
Google translation;
"Potential targeted molecular therapy against pancreatic cancer
03-28-2022
Pancreatic cancer is the most aggressive and least curable of all malignant tumors in humans. In 2020 it caused more than 400,000 deaths worldwide. In Spain, it is the third cause of death from cancer, although it is the ninth most common. A UB team coordinated by Dra. Neus Agell, professor in the Biomedicine Department of the Faculty of Medicine and Health Sciences, has synthesized a new compound with the potential to become a future therapy against this type of tumour.
The new product is a peptidomimetic, which is able to block the activity of the KRAS oncogene, one of the most important therapeutic targets in the fight against this disease. To date, oncogenic KRAS mutations have been detected in 90% of pancreatic tumors.
The molecule developed by the UB team would be able to block the interactions of KRAS with other proteins, necessary for its oncogenic activity, and thus inhibit tumor progression.
The results of the first experiments carried out with the new compound in pancreatic cancer cell lines ( in vitro ) are very promising, and the effects observed are even better than those currently obtained with other targeted therapies. In addition, this compound could inhibit the activity of different oncogenic mutants of KRAS.
The fact that this molecule is a peptidomimetic offers several advantages, as these compounds are more effective at blocking protein interaction sites than other commonly used smaller drugs. On the other hand, they have a lower molecular weight than antibodies and are therefore easier to synthesize, cheaper to produce and less immunogenic.
The next step in this research will be to conduct a proof of concept of the drug in vivo in mice to validate its effects as a therapeutic compound against pancreatic cancer."
Sign In
Follow the stocks
